Company

Maze Therapeutics, Inc.

San Francisco biotech developing precision medicines for chronic kidney disease, with a lead focus on APOL1 kidney disease.

About

Founded in 2018 in San Francisco, US, Maze Therapeutics, Inc. was established by Bernhard Klein, Jonathan Widawski, Maria Mesquita and Thomas M. Maria Mesquita is CEO. The company develops medicines that mimic rare protective genetic variants, with a focus on APOL1 kidney disease, and uses its Compass platform to inform their design. In February 2026 it raised USD 40 million in venture debt from Hercules Capital to support operations and replace its prior loan facility. It has completed 5 deals, and its current valuation is USD 485.46 mn. Its listed stage is Series D.

3Funding rounds

16Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in